|1.||Rokita, Hanna: 11 articles (10/2015 - 04/2005)|
|2.||Cheung, Nai-Kong V: 10 articles (05/2015 - 06/2002)|
|3.||Horwacik, Irena: 8 articles (10/2015 - 04/2005)|
|4.||Kozbor, Danuta: 6 articles (03/2010 - 04/2005)|
|5.||Kowalczyk, Aleksandra: 5 articles (01/2015 - 04/2005)|
|6.||Ahmed, Mahiuddin: 4 articles (05/2015 - 01/2013)|
|7.||Wierzbicki, Andrzej: 4 articles (11/2009 - 04/2005)|
|8.||Furukawa, Koichi: 4 articles (05/2004 - 07/2002)|
|9.||Boratyn, Elżbieta: 3 articles (09/2015 - 12/2013)|
|10.||Durbas, Małgorzata: 3 articles (09/2015 - 12/2013)|
01/01/1992 - "A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a."
09/01/2015 - "Mechanisms leading to inhibitory effects of an anti-GD2 ganglioside (GD2) 14G2a mouse monoclonal antibody (mAb) and PI3K/Akt/mTOR pathway inhibitors on human neuroblastoma cell survival were studied in vitro. "
09/01/2015 - "GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines."
10/30/2014 - "Primary human NKT cells were engineered to express a CAR against the GD2 ganglioside (CAR.GD2), which is highly expressed by neuroblastoma (NB). "
12/01/2013 - "The mechanism of the inhibitory effect of anti-GD2 ganglioside (GD2) 14G2a mouse monoclonal antibody (mAb) on human neuroblastoma cells survival was studied in vitro. "
08/01/2003 - "Taking these results together, our studies demonstrate that the TG mice have significant anti-tumor characteristics, probably due to CDC and NK cell expansion and activation with anti-ganglioside GD2 antibody."
07/01/1995 - "Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients."
05/22/2015 - "Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8."
01/01/2015 - "Immunohistological analysis of the biopsy samples showed strongly positive Ganglioside GD2-staining cells, whereas almost all of the tumor cells in the resected specimen were Ganglioside GD2-negative; cells were very weakly stained. "
01/01/2014 - "Ganglioside GD2 in reception and transduction of cell death signal in tumor cells."
|3.||Melanoma (Melanoma, Malignant)
06/01/1997 - "The GD2 ganglioside is a cell-surface component that appears on the surface of metastatic melanoma cells and is a marker for the progression of the disease. "
06/01/1997 - "The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside."
06/01/1992 - "These results suggest that cell surface GM2 and GD2 ganglioside expression in human melanoma cells is intimately associated with several cellular biological properties, such as drug or radiation sensitivity and cellular differentiation."
09/01/1984 - "Ganglioside GD2 is expressed on membranes of human melanoma cells and induces antibody responses in patients with melanoma. "
11/01/1986 - "Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2."
|4.||Osteosarcoma (Osteogenic Sarcoma)
01/01/2015 - "Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma."
02/15/2014 - "Ganglioside GD2 is highly expressed on osteosarcomas. "
02/15/2014 - "Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma."
07/01/1995 - "A phase I trial of a murine anti-ganglioside (GD2) monoclonal antibody (mAb) 14G2a was conducted in 14 neuroblastoma patients and 1 osteosarcoma patient to assess its safety, toxicity and pharmacokinetics in pediatric patients. "
01/01/2015 - "Ganglioside GD2 has been previously found on the cell surface in various tumor types, including osteosarcomas. "
|5.||Neuroectodermal Tumors (Neuroectodermal Tumor)
12/15/2012 - "The ganglioside GD2 is an attractive target for immunotherapy of neuroectodermal tumors. "
05/22/2015 - "Ganglioside GD2 is highly expressed on neuroectodermal tumors and an attractive therapeutic target for antibodies that have already shown some clinical efficacy. "
12/01/1982 - "Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2."
11/01/2008 - "The GD2 ganglioside expressed on neuroectodermal tumor cells has been used as a target for passive and active immunotherapy in patients with malignant melanoma and neuroblastoma. "
09/01/2007 - "The GD2 ganglioside expressed on neuroectodermal tumor cells is weakly immunogenic in tumor-bearing patients and induces predominantly IgM antibody responses in the immunized host. "
|2.||Complement System Proteins (Complement)
|4.||Immunoglobulin G (IgG)
|7.||Phosphopyruvate Hydratase (Enolase)
|9.||HLA Antigens (Human Leukocyte Antigens)
|2.||Heterologous Transplantation (Xenotransplantation)
|5.||Drug Therapy (Chemotherapy)